Biomolecular sensors for advanced physiological monitoring

Abstract

Body-based biomolecular sensing systems, including wearable, implantable and consumable sensors allow comprehensive health-related monitoring. Glucose sensors have long dominated wearable bioanalysis applications owing to their robust continuous detection of glucose, which has not yet been achieved for other biomarkers. However, access to diverse biological fluids and the development of reagentless sensing approaches may enable the design of body-based sensing systems for various analytes. Importantly, enhancing the selectivity and sensitivity of biomolecular sensors is essential for biomarker detection in complex physiological conditions. In this Review, we discuss approaches for the signal amplification of biomolecular sensors, including techniques to overcome Debye and mass transport limitations, and selectivity improvement, such as the integration of artificial affinity recognition elements. We highlight reagentless sensing approaches that can enable sequential real-time measurements, for example, the implementation of thin-film transistors in wearable devices. In addition to sensor construction, careful consideration of physical, psychological and security concerns related to body-based sensor integration is required to ensure that the transition from the laboratory to the human body is as seamless as possible.

Continuous monitoring of diverse biomolecular signatures has the potential to transform our understanding of personalized and preventative medicine. This Review Article discusses the emerging trends and pertinent considerations for the development of a new generation of body-based biomolecular sensors for in vivo measurement.

Key points

• Glucose sensors traditionally dominate the commercial sensing market, but sensors for alternative analytes could advance personalized health care in coming decades.

• Body-based biomolecular sensors, including wearable, implantable and ingestible sensors, provide simple and continuous access to user biomolecular data through various biological fluids.

• Continuous monitoring requires kinetically favourable receptors and sensing mechanisms capable of detecting analytes without user intervention.

• In addition to sensor efficacy, body-based systems require careful consideration of physical, psychological and security concerns related to device use and data handling.

Introduction

Biomolecular sensing is a rapidly growing interdisciplinary field. By combining engineering, chemistry, biology, physics, medicine and computational data analytics, sensors have been developed for the real-time monitoring of various physiological conditions. However, in spite of the identification of new sensing mechanisms and unique biomolecular targets, there remains a gap between the number of laboratory-developed sensors and commercialized products. Despite major advances in analyte targeting, signal amplification and sensor portability, it remains challenging to match the practicality and performance of simple enzymatic glucose sensors in systems that detect other analytes. Glucose sensors use specific enzymes (for example, glucose oxidase and glucose dehydrogenase) capable of producing highly amplified responses (for example, through high catalytic turnover) in a continuous manner, which is not easily achievable for other small-molecule, protein and nucleic-acid analytes. The development and adoption of body-based biomolecular sensing platforms (for example, wearables and implantables) requires continuous-sensing mechanisms with sensitivities and specificities comparable to those of glucose sensors. Therefore, the continued exploration of these body-based platforms is key to expanding biomolecular analysis beyond simple metabolite detection, to enable comprehensive physiological monitoring and inform clinical decision-making.

Historically, biological sensors or biosensors were named for their incorporation of a biological component to recognize and detect analytes. These biorecognition elements were necessary because the intricacy and selectivity of biological macromolecules was difficult to imitate. However, advances in the development of synthetic recognition elements, such as molecularly imprinted polymers and artificial enzymes, have enabled sensors to achieve selectivity comparable to that of their natural counterparts¹. At present, we use the term biomolecular sensor to more generally describe all sensors aimed at detecting biomolecules or other biologically relevant molecules, shifting the focus away from the origin of the selected recognition component, and towards the more relevant nature of the analyte being detected.

In terms of composition, biomolecular sensing systems typically comprise four main components: the analyte, which is the biomolecule being detected; the recognition element, which interacts with the analyte and provides some degree of selectivity; the transducer, which converts the analyte-recognition element interaction into a readable signal; and the analysis system, which interprets the received signals. In addition to these physical components, there are several key terms that are vital to understanding and comparing sensing schemes: the limit of detection (LoD) describes the lowest analyte concentration that can be consistently detected by a sensor; sensitivity, though often erroneously used interchangeably with LoD, refers to the ability of a sensor to differentiate between similar input concentrations; selectivity describes the ability of a sensor to selectively target certain analytes; specificity, which serves as an ultimate form of selectivity, describes the ability of a sensor to target a single analyte; linear range describes the analyte concentration range over which a sensor produces a proportional response; and physiological range describes the physiologically relevant concentration range of the analyte, which ideally falls within the linear range of the sensor.

The concept of biomolecular sensing existed millennia prior to any understanding of the molecular concept (Fig. 1), with the analysis of urine being conducted in civilizations as old as Sumer (~4000 BC)². The most considerable and lasting of these findings was the association between polyuria and sweet-tasting urine, recorded by the Indian physician Sushruta (~600 BC)³. Over the next two millennia, it was not uncommon for individuals referred to as water tasters to diagnose diabetes-like illness by tasting urine and assessing its sweetness⁴. The connection between diabetes and sweet urine was rediscovered and made mainstream in Europe by Thomas Willis (~1679)³. Over the next few centuries, scholars discovered that sugar was responsible for the sweetness of diabetic urine and established chemical tests to determine its presence⁵. These tests, including Trommer’s test, Fehling’s test and Benedict’s test, exploited sugar-assisted reduction of copper species to produce colorimetric changes and diagnose diabetes^3,5. Although these tests were rather non-specific, they can be seen as the predecessors of modern biomolecular sensors.

Fig. 1. Timeline of biomolecular sensor development.

Timeline of major events regarding the evolution of biomolecular sensing, including the first evidence of urine analysis²; the first connection between sweet urine and diabetes-like illness³; the rediscovery of the connection between sweet urine and diabetes in Europe³; the development of primitive metal salt glucose tests^3,5; the first incorporation of a biological recognition element into a colorimetric biomolecular sensor⁸; the first proposed electrochemical biomolecular sensor⁶; the first commercial, portable glucose sensor⁹; the first commercial electrochemical glucose sensor¹²; and the US Food and Drug Administration (FDA) approval of the first continuous glucose monitor¹³.

The first modern biomolecular sensor is typically attributed to Leland Clark for his 1962 proposal⁶ to incorporate glucose oxidase enzymes into his previously developed oxygen electrode⁷. However, the Miles–Ames laboratory also made substantial contributions with the development of a colorimetric glucose oxidase test strip in 1957 (ref. ⁸). In 1970, the same laboratory released the first portable blood glucose meter, a landmark achievement in portable biomolecular analysis⁹. Clark eventually commercialized his electrochemical glucose monitor in 1975 (ref. ¹⁰). In the 1980s, as glucose monitoring became more mainstream, many alternative colorimetric glucose systems made their way to market¹¹. Although it was difficult to miniaturize them, the first portable electrochemical glucose monitor eventually reached the market in 1987 and quickly dominated its colorimetric competitors¹². This landmark led to market-wide adoption of electrochemical sensing, with most companies replacing their colorimetric devices with electrochemical ones that are still on the market today. Finally, in 1999, the first continuous glucose monitor received US Food and Drug Administration (FDA) approval¹³, sparking interest in the development of body-based sensing platforms.

The twenty-first century has brought with it a new wave of body-based sensing systems, with many large life sciences companies marketing their own continuous glucose monitoring system. While glucose measurement remains at the forefront of sensor innovation, the development of commercial sensors for alternative analytes has lagged behind, with the exception of a few other metabolites (for example, cholesterol). However, there is an abundance of other biochemical indicators (for example, proteins and DNA) that can provide invaluable information on physiological status. As sensor development continues towards new body-based platforms capable of long-term measurements, the number of analytes that can be reliably detected will hopefully continue to expand and allow these systems to realize their diagnostic potential.

This Review summarizes emerging biomolecular sensors, tackling two main challenges. The first challenge is the transition of sensors from laboratory-based assays to body-based systems to develop self-contained biomolecular sensors that are wearable, implantable or consumable and can easily be incorporated into everyday life. The second challenge is to expand biomolecular sensors beyond glucose detection, to realize practical and commercial devices for a broader range of relevant physiological markers (Box 1). To overcome these challenges requires biomolecular sensing approaches that are more sensitive, specific and amenable to continuous monitoring than ever before. Here we highlight many of the cutting-edge strategies expected to facilitate the development of new sensing devices. In addition, we explore relevant considerations regarding biological fluid compatibility and sensor design to ensure seamless lab-to-body transition.

Box 1 Commercializing biomolecular sensors beyond glucose.

As of 2022, the global market for biomolecular sensors exceeded US$28 billion and is expected to surpass US$58 billion over the next 10 years²⁰⁴. Although the past 50 years of biomolecular sensing have seen considerable financial investment and industrial development, this has primarily focused on advancing glucose detection. This is partly because of the high demand for daily diabetic glucose monitoring, but also because of the simple enzymatic detection method by which glucose can be measured. There is certainly no shortage of sensing mechanisms for other analytes, and many sensing approaches have been developed for various fluids, but there is a lack of detection schemes that can easily be implemented in commercial products. To accommodate biomarkers and enable commercialization, several hurdles must be overcome.

Improved understanding of the biochemistry–physiology relationship

The broad adoption of glucose monitoring can be attributed to the direct link between levels of glucose and health, a link that can be difficult to make for other more complex biomarkers. An array of analytes have been studied for their association with health conditions, but there is a need for a deeper understanding of how biomarkers fluctuate in specific biological fluids, especially in non-blood biological fluids, so that physiological conditions can be tracked accurately¹⁵⁵. For example, complex biomarkers, such as cytokines, have immense potential to inform critical health decisions, but their polycausal fluctuations, combined with our still elementary understanding of their stimulation, make it difficult to employ them for medical assessment.

Developing detection strategies with simplicity comparable to glucose sensors

Although enzymatic detection is simple and easily implementable, the lack of available enzymes for most analytes necessitates more advanced sensing strategies, such as affinity-based approaches. However, although affinity-based sensors have shown promise, their reliance on affinity interactions makes them more difficult to implement in continuous-sensing systems⁸⁷. Such sensors must be able to reset themselves in a timely manner, maintain sensor integrity and avoid biasing bulk analyte concentrations. Further development of kinetically controllable recognition elements, robust anti-fouling strategies and reliable reagentless detection approaches will help to hasten their adoption^86,92,117.

Identification and prediction of societal needs

The translation of biomolecular sensors requires investment of time, money and knowledge. Therefore, sensors must address issues that are central to current needs. For example, the ongoing SARS-CoV-2 pandemic has driven considerable development of viral detection methods¹¹⁸. The ability to identify emerging sensing applications is an important factor in guiding a sensor to the market.

Strategies for signal amplification

Sensitivity, specificity and adaptability to new analytes are the major challenges for biomolecular analysis¹⁴. Therefore, many amplification strategies have been developed to enable lower LoDs and higher sensitivities. These strategies can be implemented at any level of sensor development to help to achieve practical physiological monitoring.

Intracellular sensors

Intracellular sensors go beyond secreted (for example, insulin) and membrane-bound biomarkers (for example, viral surface proteins) to provide localized information at the cellular level (for example, quantifying mRNA expression in breast cancer cells and detecting overexpression of cytosolic cathepsin B in adenocarcinoma cells)^15,16. They are also sensitivity enhancers, given the small size of the cell and the fact that intracellular concentrations often surpass those in biological fluids. These sensors allow single-cell diagnosis by probing cytoplasmic regions and enable access to diverse high-concentration biomarkers (Fig. 2a). Intracellular analysis is typically achieved by either direct insertion of nanostructures into the cytosol to probe¹⁶ or extract¹⁷ its contents, or indirect intake and expression of a genetic sensing framework; for example, through reporter gene activation upon interaction with intracellular human immunodeficiency virus (HIV) proteins¹⁸. These intracellular approaches have the potential to considerably amplify cell-localized biological phenomena (such as cytoplasmic protein overexpression) for diagnostic purposes.

Fig. 2. Strategies for amplifying biomolecular interactions.

a, Intracellular sensing allows access to new, high-concentration biomarkers. b, Surrogate biomarkers can provide alternative detection pathways for trace analytes. c, Synthetic biomarkers can be introduced to the body to amplify biomolecular processes and enable their detection. d, Nanozymes and DNAzymes provide alternative catalytic routes for analyte monitoring. e, Mass transport advances, including analyte-guiding nanochannels, superhydrophobic transport metamaterials and analyte mixing micromotors increase the rate of interaction between an analyte and its recognition element. f, Organic electrochemical transistors serve as powerful amplifiers for biomolecular interactions. g, Reporter multimerization enhances the signal output from affinity interactions. h, Debye length-manipulating approaches, including structure-switching receptors, nanostructure-mediated electron transfer and membrane-mediated Debye extension bypass traditional Debye limitations to extend transducer influence and increase signal generation. i, Computational approaches, combined with multiplexed analysis, may allow health state amplification for predictive medicine. Part c is adapted from ref. ²², Springer Nature Limited. Part e (analyte-guiding nanochannel) is adapted from ref. ³⁹, Springer Nature Limited. Part e (superhydrophobic transport metamaterials) is adapted from ref. ⁴⁰, Springer Nature Limited. Part f is adapted from ref. ⁴⁴, Springer Nature Limited. Part h (structure-switching receptor) from Nakatsuka, N. et al. Aptamer-field-effect transistors overcome Debye length limitations for small-molecule sensing. Science 362, 319–324 (2018)⁵¹. Adapted with permission from AAAS. Part h (nanostructure-mediated electron transfer) is adapted from ref. ⁵³, CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Part h (membrane-mediated Debye extension) is adapted from ref. ⁵⁴, Springer Nature Limited.

Surrogate biomarkers

Sensor development has long focused on the assessment of biological conditions through directly related molecular targets, such as targeting viral surface proteins to detect a virus. Yet there is an abundance of additional targets or surrogate biomarkers (Fig. 2b) that are less intuitive but still correlate with physiological conditions¹⁹. Surrogate markers may also be present at higher concentrations than the direct target, and can thus amplify a biochemical signal. Advances in the understanding of molecular pathways can reveal new biological relationships and help to access a broader library of health indicators. For example, precursor or metabolite molecules can be targeted, such as tyrosine as precursor to norepinephrine — a neurological indicator²⁰. Another approach is the targeting of indirectly related proteins that show high condition correlation, for example, measuring neurofilament light chain protein as an indicator of inflammatory brain demyelination²¹. These simple methods can provide precise indirect estimates of trace molecules or hidden biological events.

Synthetic biomarkers

The pool of endogenous biomarkers is large, but it is not limitless. Alternatively, synthetic biomarkers (Fig. 2c) that are designed to interact with biomolecules can be introduced into the body (for example, through injection) to indicate and amplify physiological conditions (for example, by reacting with an overexpressed enzyme)^22,23. Synthetic biomarkers can have various configurations; however, all of them contain two essential components: a recognition region (for example, substrates²⁴ and promoter sequences²⁵) to target the biochemical process and a reporter region (for example, volatile organic compounds²⁴ and genes²⁵) to signal its presence. Synthetic markers can bypass common endogenous biomarker issues (for example, short half-lives and low concentrations), and detect previously inaccessible or subtle health states. For example, volatile reporter molecule-linked peptides injected into mice are cleaved by neutrophil elastase, to indicate its elevated activity, which is associated with several illnesses (such as pulmonary bacterial infections and alpha-1 antitrypsin deficiency)²⁴.

Catalyst-mediated amplification

Enzymes are considered the ideal recognition element owing to their excellent selectivity and natural catalytic ability; however, they are restricted by the analytes they can target. Therefore, the discovery and fabrication of alternative catalysts (Fig. 2d) is important for universal high-sensitivity sensing.

Nanozymes are nanomaterials that possess catalytic ability and can replace enzymes in biomolecular sensing. These include nanoparticles²⁶, metal–organic frameworks (MOFs)²⁷, and many other nanomaterials²⁸ capable of catalysing biochemical reactions and generating amplified biomolecular responses. For example, peroxidase-like MOFs capable of catalysing o-phenylenediamine to 2,2-diaminoazobenzene enable sensitive detection of Staphylococcus aureus with a LoD of only 6 colony-forming units (CFU) ml^–1 (ref. ²⁹). Additionally, single-atom nanozymes have atomically dispersed metal active sites that maximize catalytic efficiency, allow for tunable selectivity, and enable reaction kinetics similar to that of natural enzymes^1,30,31. Moreover, computational approaches and artificial intelligence can be applied to the discovery of artificial catalysts (for example, superoxide-dismutase nanozymes and carbon dioxide electrocatalysts)^32,33.

DNA catalysts, or DNAzymes, can also amplify biomolecular signals and offer alternative catalytic routes for sensing. DNAzymes catalyse various reactions, including RNA cleavage, RNA ligation and alkyne–azide cycloaddition^34–36. These reactions can be implemented in a variety of ways to detect metal ions, small molecules, nucleic acids and proteins through a combination of a catalytic event and a released reporter molecule (for example, cleaving of a dye-conjugated RNA sequence). For example, DNAzymes selected to react with specific bacteria lysates can detect bacteria in single digits per millilitre in unprocessed blood samples^37,38. In addition, the complementary nature of DNA within DNAzymes allows for programmable capture and release of the substrate, and easy integration with other functional nucleic acids (for example, extension of the DNAzyme sequence to include an aptamer sequence that can bind the analyte and provide additional selectivity)³⁴.

Overcoming mass transport limitations

The sensitivities and LoDs of biomolecular sensors do not rely on the bulk concentrations of analyte in solution but on the localized amount of analyte interacting with the recognition component of the sensor. Therefore, maximizing the analyte-recognition element interactions is important to ensure sensitive and fast detection. Several strategies have been developed to overcome the limitations caused by slow mass transport of molecules and thus slow diffusion (Fig. 2e) to improve biomolecular recognition and to amplify early signal responses. These strategies include designing synthetic nanochannels to maximize transport efficiency³⁹, using superhydrophobic surfaces to control molecule localization⁴⁰ and using molecular micromotors to mix solutions and accelerate mass transport⁴¹. In addition, DNA nanostructures can improve surface probe distribution and reduce probe crowding, allowing for enhanced analyte association⁴². Microfluidic approaches for sample collection and transport can maximize mass transport efficiency, in addition to being compatible with wearable and implantable devices⁴³.

Organic electrochemical transistors

Organic electrochemical transistors (OECTs) (Fig. 2f) can act as signal-amplifying components in biomolecular sensing and other bioelectronic devices⁴⁴. OECTs contain three main properties which, when combined, set them apart from other field-effect transistors. First, they possess an organic semiconductor channel (such as poly(3,4-ethylenedioxythiophene) polystyrene sulfonate, PEDOT:PSS) that bridges the source and drain electrodes. Second, they possess an electrolyte between the channel and gate electrode. Third and most importantly, they allow for full penetration of electrolyte ions into the semiconductor channel⁴⁵. Because semiconductor doping is reliant on ion penetration, OECTs can generate very large drain currents with small gate voltages, which makes them excellent signal amplifiers for biomolecular interactions^44,46. For example, an interdigitated OECT sensor for adenosine triphosphate (ATP) achieves a LoD of 10 pM, which is nearly four orders of magnitude better than an amperometric transduction approach using the same recognition element⁴⁷. The inexpensive fabrication costs of OECTs, as well as their capacity for flexible electronic integration, make these components attractive candidates for wearable and implantable devices⁴⁸.

Reporter multimerization

A simple method of amplifying biomolecular interactions at the transduction level is to increase the amount of signal generated by each analyte. Typically, affinity interactions result in a 1:1 ratio between signal and interaction. However, this ratio can be increased through simple incorporation of multiple reporter molecules (Fig. 2g) into the recognition element complex. For example, incorporation of multiple methylene blue redox markers into a C-reactive protein sensor enhances signal output and enables a LoD of 1 pM, which is considerably lower than that of previous electrochemical and optical approaches using single reporter molecules⁴⁹. Alternatively, secondary reporter complexes in the form of oligonucleotide systems or reporter-labelled nanomaterials (for example, dendrimers) may be used to produce amplified responses⁵⁰. However, many of these multimerization amplification strategies are designed for use in more traditional immunoassays with externally added reporter molecules, and thus may not be compatible with body-based biomolecular sensing. This encourages the development of methods that focus on multimerization of recognition elements and require no external reagents, which are more compatible with continuous in vivo detection.

Overcoming Debye limitations

The screening of surface-bound charges by mobile ions beyond the Debye length, which is the effective sensing range, is a key obstacle in the development of high-sensitivity electronic sensors⁵¹. Although this issue is often avoided through alterations to the buffer solution (for example, decreased ionic strength), this approach is unrealistic for biofluid analysis⁵². Thus, several strategies have been introduced to overcome Debye length limitations and to amplify biomolecular interactions (Fig. 2h). Among these strategies is inducing near-electrode conformational changes to signal distant interactions⁵¹, using nanostructured materials to accelerate electron transfer⁵³, and employing membrane-encapsulated ion-free water layers to extend the Debye length⁵⁴.

Multiplexing and molecular data fusion

Multiplexing or using multiple markers allows the amplification of changes in physiological signals by increasing the number of biomolecular targets. Thus, sampling of multiple molecular avenues (for example, inflammatory, hormonal and metabolic) provides a more comprehensive health assessment⁵⁵. The fusion and analysis of multiple molecular data (Fig. 2i) through artificially intelligent approaches, such as machine learning, can expand the capability of sensors to identify and diagnose physiological conditions faster, earlier and with more accuracy than techniques relying on single analyte analysis^56–58. In addition, multiplexed controls (for example, additional sensors with non-specific recognition elements) allow better insight into sensor stability by providing separate channels to monitor sensor degradation.

Strategies for selectivity improvement

The incorporation of biological recognition elements that selectively detect biologically relevant molecules into molecular sensing approaches can improve selectivity^6,8. Proteins, DNA and synthetic alternatives (such as polymers and nanoparticles) can be applied as recognition elements for specific analytes^59,60. Although enzymes are ideal recognition elements owing to their high specificity and natural signal amplification through high catalytic turnover, most biomolecular targets do not have specific enzyme catalysts and thus require alternative recognition approaches. Robust affinity recognition elements (affinity receptors) that induce highly specific association interactions with their target are necessary to develop body-based biomolecular sensors. These recognition elements should be able to withstand the presence of high concentration interferants in native biofluids, remain stable during daily wear and tear, and possess the resolution and dynamic capabilities to capture physiologically relevant changes in biomarker levels. Here, we discuss the current state of affinity recognition elements, explore strategies to overcome non-specific binding and biofouling, and analyse the compatibility of various recognition elements for in vivo real-time monitoring.

Natural and artificial affinity receptors

Antibodies are the most popular biological affinity receptors employed in sensors (Fig. 3a). They are generated in vivo in response to specific immunostimulation to selectively bind targets under physiological conditions. Antibodies have high binding affinities, selectivity and sensitivity to detect biomarkers at picomolar to nanomolar concentrations. However, antibodies are fragile, highly sensitive to temperature and pH changes, exhibit batch-dependent variation, and have high production costs, which greatly limits their use in bioelectronic applications⁵⁹. Antibody mimetics with high ligand-binding affinity can be designed in the form of antibody fragments⁵⁹ (for example, nanobodies⁶¹) and engineered proteins (for example, avimers⁶², affimers⁶³ and affibodies⁶⁴). Compared to antibodies, these engineered receptors are smaller in size, have higher thermal stability, and can be engineered as multimers to increase avidity^59,61. In addition, in vitro technologies such as phage display and ribosome display enable rapid, efficient and inexpensive selection of high-affinity protein-based binders^65,66. However, although they are effective, these engineered alternatives often fail to outcompete antibodies in assay performance; this is probably due to their inability to mimic the glycosylation patterns and post-translational modifications of antibodies, which confer additional selectivity.

Fig. 3. Considerations for biomolecular sensor recognition element selection.

a, Classes of available recognition elements (protein, DNA and synthetic) including both traditional and emerging receptors. b, Strategies for prevention of non-specific binding (NSB). c, Recognition-element-based strategies for continuous monitoring include catalyst-mediated detection, kinetic control of analyte binding and release, and receptor regeneration following analyte attachment. k_off, dissociation rate constant; k_on, association rate constant; SB, specific binding; SOMAmer, slow off-rate modified aptamer; ssDNA, single-stranded DNA; ssRNA, single-stranded RNA.

Functional nucleic acids are promising affinity recognition element alternatives to antibodies. Aptamers are single-stranded nucleic acids generated in vitro through the systematic evolution of ligands by exponential enrichment (SELEX), in which sequences are selected to bind to a specific target, ranging from metal ions to whole cells^67,68. SELEX allows the generation of affinity receptors for a broad range of targets, including toxic, non-immunogenic and small-molecule biomarkers that are difficult to target with antibodies^69,70. Aptamers are particularly promising for implementation in body-based sensors owing to their simple and inexpensive mass synthesis, minimal batch-to-batch variation, high thermal stability, non-immunogenic properties and their amenability to site-specific chemical modification. As such, aptamers have been demonstrated in several wearable and implantable sensors (for example, in continuous cortisol- and serotonin-monitoring systems)^71,72.

However, aptamers are inherently prone to nonspecific binding owing to their intrinsic negative charge and the large variety of RNA- and DNA-binding proteins present in body fluids⁷³. In addition, they are susceptible to nucleases in biological fluids and sensitive to changes in environmental conditions, such as pH, temperature and salt concentration. Alternatively, chemically modified aptamers with non-natural nucleic acids can have low nonspecific binding, and improved stability and binding affinity (such as SOMAmers⁷⁴ modified to have slow analyte dissociation)⁷⁵. SELEX approaches run in biological fluids or directly in live animals can isolate aptamers that maintain high performance under physiological conditions^76,77. Additionally, strategies to resist nuclease degradation such as using chemical alterations or surface coatings^78,79 can minimize probe loss.

Synthetic recognition elements that are not based on biological monomers (such as molecularly imprinted polymers⁶⁰ and supramolecular systems⁸⁰) also show promise as selective receptors for biomolecular sensors.

Nonspecific binding

A key challenge in the translation of biomolecular sensors is nonspecific binding, which can occur on both the sensor surface (biofouling) and the recognition element (cross-reactivity)⁷³. Biofouling is driven by the accumulation of cells, proteins or other species on the sensor surface through nonspecific interactions. This adsorption process hinders the diffusion of analytes to the sensor and leads to signal loss over time⁸¹. Cross-reactivity arises from recognition elements that interact with molecules other than the analyte of interest to produce false-positive responses. These interferants may have affinities close to that of the analyte, or they may be present in such high concentrations that they associate to a considerable degree at equilibrium. In biological fluids, high protein content compared to that of the analyte can cause substantial nonspecific binding that may appear as false positive signals⁷³. Strategies and approaches, such as using protective coatings and exploiting kinetic differences between analyte and interferant must therefore be developed to minimize these extraneous interactions (Fig. 3b).

Generally, anti-fouling strategies aim to either fill the gaps in a sensing surface using a blocking agent (for example, bovine serum albumin (BSA) and casein) or to coat the entire sensing surface with an anti-fouling layer (for example, poly(ethylene glycol) and zwitterionic polymers such as derivatized polycarboxybetaine)^73,82,83. More complex anti-fouling layers, based on bioinspired materials (for example, slippery liquid-infused porous surfaces inspired by pitcher plants)⁸⁴, hydrogels (for example, polyacrylamide copolymer gels)^85,86 and nanocomposites (for example, cross-linked BSA impregnated with conducting nanomaterials)^87,88 also show fouling resistance in vivo. Additionally, methods have been developed to distinguish analyte binding from nonspecific interferent binding. One such approach exploits the affinity differences between analyte and interferant to physically remove weakly bound entities with an external force, for example by using an alternating electric field⁸⁹. This approach allows active removal of interfering species, such as nonspecific IgG without ejection of the target HER2 protein. The inclusion of a reference or control sensor with a non-specific receptor (for example, scrambled aptamer sequence⁷¹) is another way to differentiate between real and non-specific signals. Alternatively, the molecular recognition approach itself can confer some resistance to nonspecific interactions. Sensing mechanisms that rely on an analyte-triggered event (for example, structure-switching aptamers⁵¹) are less prone to nonspecific signal interference than sensors that rely on bulk property changes. Similarly, stochastic sensing approaches (for example, solid-state nanopores⁹⁰) that can computationally distinguish between analyte and interferant are highly resistant to nonspecific behaviour.

Continuous real-time monitoring

As an alternative to single-use sensors, body-based biomolecular sensors require sensor regeneration and reliability. Thus, sensors must be able to detect analytes using reversible molecular interactions, ensure minimal time between readings and provide continuous data with negligible hysteresis. Continuous monitoring is challenging, especially with high-affinity recognition elements that exhibit slow dissociation kinetics⁹¹; however, there are several solutions to overcoming such limitations (Fig. 3c). A receptor with fast binding kinetics (for example, an aptamer selected for high on/off rate) is ideal for continuous monitoring because it allows rapid equilibration with the surrounding fluid⁹². However, as these rapid kinetics edge closer to real-time monitoring, this temporal resolution often comes at the cost of sensor LoD. Therefore, biomolecular sensors that employ such recognition elements must also use highly sensitive transduction mechanisms (for example, transistor-based approaches) to compensate for sensitivity loss⁹³. In addition, a proper fluid-sampling system (for example, microfluidic integration) is desirable to provide effective and rapid transport of the biological fluid over the sensor to ensure a reproducible, timely and accurate signal, along with negligible sample contamination and carryover.

Real-time monitoring can also be achieved through the regeneration of recognition elements after each measurement, using either chemical, thermal or electrochemical approaches⁹⁴. Chemical regeneration methods rely on surface and fluid property alterations through the application of acids, bases or other solvents. However, these approaches can damage biological receptors and are not compatible with body-based biomolecular analysis. Thermal regeneration methods are more feasible for body-based sensing, relying on localized warming using miniaturized heating elements, and are particularly promising for nucleic-acid-based receptors⁹⁵. Finally, electrochemical regeneration approaches employ electrical pulses or other waveforms to manipulate affinity interactions without risking damage to receptors⁹⁶.

Approaches for continuous monitoring

Continuous monitoring requires complementary sensing approaches that enable real-time detection in biological fluids⁹⁷. Most available biomolecular sensing methods rely on secondary reporters (for example, sandwich assays), indirect reporters (for example, steric hindrance assays) or chromatographic systems (for example, lateral flow assays). However, such techniques are incompatible with body-based biomolecular sensing owing to their dependence on external manipulation and washing steps. Some approaches avoid the need for such external interventions by combining recognition and reporting steps into one process. However, these methods typically rely on specialized receptors with intrinsic activity such as enzyme catalysts that are only available for a small subset of analytes. Thus, the development of universal reagentless platforms that offer versatility in target analysis, and employ self-contained reagent-free mechanisms, is crucial for the widescale adoption of body-based sensors.

Electrochemical aptamer-based sensors

Electrochemical aptamer-based (E-AB) sensors (Fig. 4a) allow reagentless, label-free detection of small molecules and proteins⁹⁸. E-AB sensors use electrode-bound aptamers with terminal redox reporters to recognize and bind analytes. Analyte detection is achieved through target-induced proximity changes between the redox reporter and the electrode surface, which alters the received Faradaic current. E-AB sensors have been optimized to establish a detailed theoretical framework for their molecular interactions⁹⁹, and enable their implementation in in vivo systems^99–101. Moreover, E-AB sensors have excellent temporal resolution upon sequential in vivo measurements, for example, for the detection of plasma phenylalanine in rats¹⁰². Furthermore, E-AB molecular probes can be incorporated into implantable devices to offer non-invasive continuous monitoring. For example, an E-AB microelectrode sensor is used for the continuous measurement of doxorubicin in mouse tumour tissue¹⁰³. Although E-AB approaches expand analyte diversity for continuous monitoring, they are restricted by the availability of aptamer sequences that can bind relevant targets and undergo sufficient conformational changes between their unbound and bound states.

Fig. 4. Strategies for reagentless biomolecular analysis.

a, Electrochemical aptamer-based sensors rely on aptamer binding-induced proximity changes between a redox reporter and an electrode. b, Electrochemical DNA sensors use hairpin DNA structures to detect DNA through binding-induced redox reporter proximity changes. c, DNA scaffold sensors rely on steric hindrance from small receptor-bound analytes to alter redox readout. d, Protein scaffold sensors use conformational changes in redox-tagged protein receptors to detect bound analytes. e, Nanoscale molecular pendulum sensors exploit hydrodynamic differences between bound and unbound probes to temporally separate redox readout. f, Impedimetric sensors rely on interfacial capacitance changes to detect analyte binding. g, Thin-film transistors use interaction-mediated alterations in current flow to detect analyte–receptor binding. Part a is reproduced with permission from Xiao, Y., Lubin, A. A., Heeger, A. J. & Plaxco, K. W. Label-free electronic detection of thrombin in blood serum by using an aptamer-based sensor. Angew. Chem. Int. Edn Engl. 44, 5456–5459 (2005)⁹⁸. Copyright Wiley-VCH GmbH. Part b is adapted with permission from Fan, C., Plaxco, K. W. & Heeger, A. J. Electrochemical interrogation of conformational changes as a reagentless method for the sequence-specific detection of DNA. Proc. Natl Acad. Sci. USA 100, 9134–9137 (2003)¹⁰⁴. Copyright (2003) National Academy of Sciences, USA. Part e is adapted from ref. ¹¹⁷, Springer Nature Limited.

Electrochemical DNA sensors

DNA is an important biomarker for the diagnosis of disease and surveillance of physiological conditions. Electrochemical DNA (E-DNA) sensors (Fig. 4b) operate in a similar way to E-AB sensors, that is, through target-induced proximity changes between a terminal redox reporter and an electrode. However, instead of aptamers, E-DNA sensors rely on DNA hairpin probes that hybridize to nucleic acid analytes¹⁰⁴. Alternatively, E-DNA approaches can use strand displacement techniques¹⁰⁵. E-DNA sensors can be implemented into in vivo systems, for example, for the detection of pM-level DNA in whole blood¹⁰⁶. However, these sensors are often susceptible to false-positive results owing to probe degradation and non-specific interactions. In addition, ultralow concentrations of circulating DNA in physiological matrices complicates the commercial adaptation of these approaches¹⁰⁷. Ongoing research aims to overcome these challenges and enable in vivo monitoring through signal amplification and advanced probe design (for example, through the incorporation of multiple redox reporters per probe)¹⁰⁸.

DNA-scaffold-based sensors

DNA-scaffold-based sensors enable reagentless detection of proteins, nucleic acids and small molecules, relying on DNA frameworks (Fig. 4c). These sensors employ a variety of small recognition elements such as peptides that are anchored to electrodes by DNA sequences. In addition, these systems typically contain redox reporter molecules within the DNA scaffold that enable electrochemical readout^109–113. DNA-scaffold-based detection is achieved through differential access to the electrode surface of bound versus unbound probes, often through analyte-mediated steric hindrance, which leads to differences in faradaic current. DNA-scaffold-based sensors can detect analytes in complex biological fluids, for example, HIV and syphilis antibodies in human serum^110,113, making them a promising chemical approach for body-based sensing. Even though these sensors work well for small receptors, they are incompatible with larger recognition elements such as antibodies owing to slow diffusion and low baseline currents. Thus, analytes that lack corresponding small receptors, such as many large proteins, are difficult to detect with this approach. Using protein-binding DNA can be a solution for this challenge¹¹⁴, but these methods are also limited by the availability of such recognition elements.

Protein-scaffold-based sensors

Protein-scaffold-based sensors (Fig. 4d) operate on principles similar to those of their DNA counterparts, enabling reagentless detection through use of amino acid scaffolds^115,116. Like DNA scaffolds, protein scaffolds contain an electroactive reporter that confers electrochemical activity. However, protein-based approaches do not typically involve a separate recognition element, with the protein scaffold itself acting as the analyte receptor. Upon binding of the protein scaffold to its corresponding analyte, conformational changes facilitate the alteration of faradaic current received at the electrode. Protein-scaffold-based sensors can enable real-time measurements in biological fluids, for example, for the detection of Fyn kinase peptide targets in whole blood¹¹⁵. However, their dependence on protein-based receptors greatly limits the range of analytes they can detect.

Molecular pendulum-based sensors

Nanoscale molecular pendulums (NMPs) allow reagentless electrochemical sensing for continuous biomarker analysis¹¹⁷ (Fig. 4e). NMPs are comprised of two hybridized DNA strands, one of which contains a terminal ferrocene redox reporter and the other a terminal antibody. Upon application of a sufficiently positive potential, the negatively charged NMPs descend towards the electrode surface in a motion resembling that of an inverted pendulum. When the terminal ends of the NMPs fall close enough to the electrode surface, ferrocene oxidizes and produces a measurable faradaic current. Detection with NMPs occurs through differential rates of ferrocene oxidation, where hydrodynamic differences between bound and unbound antibodies dictate the rate of pendulum descent. This method allows detection of proteins and peptides (for example, troponin T, brain natriuretic peptide and the interleukin IL-6) in a variety of biological fluids, including blood, sweat, and saliva¹¹⁷. NMPs can also detect SARS-CoV-2 proteins and whole viruses in untreated clinical saliva samples¹¹⁸. However, further theoretical development and optimization is required prior to the adoption of NMP sensors in biomedical devices.

Impedance spectroscopy-based sensors

Electrochemical impedance spectroscopy (EIS) (Fig. 4f) is a powerful technique for measuring interfacial properties related to electrode-localized molecular recognition events¹¹⁹. Many EIS sensors rely on faradaic impedance, and thus require addition of external redox probes. Alternatively, non-faradaic impedance approaches enable reagentless detection without the need for sample pretreatment¹²⁰. Given the detail-rich nature of impedance measurements, these non-faradaic methods use alternative parameters (for example, double-layer capacitance¹²¹) to monitor analyte interaction with receptor-functionalized surfaces. Non-faradaic methods allow the detection of nucleic acids, proteins and many other analytes continuously in complex biological fluids (for example, detection of insulin in serum and detection of miRNAs in plasma)^122,123. However, because of their dependence on interfacial properties, impedance-based sensors are particularly susceptible to surface biofouling; thus, further research into anti-fouling strategies is required to apply these techniques in body-based systems⁸⁷.

Thin-film-transistor-based systems

Thin-film transistors (Fig. 4g) are a subset of field-effect transistors (FETs) that can be integrated into body-based sensors, showing high sensitivity, great flexibility and capacity for real-time continuous sensing¹²⁴. Similar to impedimetric approaches, FETs rely on interfacial property alterations and thus do not require external reporter molecules to indicate molecular interactions. Promising semiconductors for thin-film transistors include organic materials, such as PEDOT:PSS^45,46, carbon allotropes¹²⁵ and metal oxides⁷¹. Although these materials differ in their individual properties, for example in their conductivity, they can all facilitate continuous monitoring of a variety of analyte types in complex biological fluids. For example, FETs are used for the detection of amino-terminal pro-brain natriuretic peptide (NT-proBNP) in human serum and SARS-CoV-2 RNA in nasopharyngeal samples^46,126,127. In addition, thin-film transistors can be implemented in wearable and implantable systems for small molecule sensing in vivo (for example, wearable cortisol monitoring in human sweat and serotonin monitoring in mice using an implanted neural probe)^71,72. However, similar to EIS-based sensors, thin-film transistors are susceptible to biofouling and environmental degradation¹²⁸.

Alternative transduction approaches

Besides electrochemical and electronic detection, optical approaches can be applied for signal transduction. Here, the distance between a fluorophore and quencher are exploited, using optical analogues of E-AB sensors¹²⁹, E-DNA sensors¹²⁸, DNA/protein-scaffold-based sensors¹³⁰ and NMP sensors¹³¹. Advances in fibre optics and nanophotonics have enabled optical body-based biomolecular sensors^132,133.

The biological fluid frontier

A variety of bodily fluids can be assessed for biomolecular analysis (Table 1; Fig. 5). Ideally, a biological fluid should be non-invasively collected or sampled, contain diverse analytes, reflect physiologically relevant biomarker concentrations, and capture transient fluctuations in targeted biomarkers. In addition, biological fluid sampling should be compatible with day-to-day life, such that sensors can take readings without the need for user handling.

Table 1.

Comparison of biological fluid suitability for various biomolecular sensing applications

Body fluid	Correlation with blood	Analyte diversity	Glucose lag time	Invasiveness	Body-based compatibility	Can be stimulated?
Urine	Medium	Low	Long	Low	Wearable	No
Blood	Not applicable	Very high	Not applicable	High	Implantable	No
Saliva	Low	Medium	15 min	Low	Wearable	Yes
Sweat	Medium	Low	10 min	Low	Wearable	Yes
Tears	High	Medium	13 min	Low	Wearable	Yes
Interstitial fluid	Very high	High	5–6 min	Medium	Wearable, implantable	No
Breath	Unknown	Low	Not applicable	Low	Wearable	Not applicable
Digestive fluid	Unknown	Medium	Not applicable	Medium	Consumable	Not applicable

Fig. 5. Biological fluid considerations for body-based sensing systems.

Approaches to incorporating body-based sensors into everyday life, showing frequently used biological fluids and specific applications for these fluids (apart from general applications that multiple fluids can be used for), and existing commercial products that can house these fluid-sampling devices.

Urine

Urine is a reliable fluid for at-home biomolecular sensing (for example, pregnancy tests) owing to its non-invasive and easy collection. Because of its direct derivation from blood, urine contains a wealth of molecular information, including metabolites, DNA, RNA and proteins, that tend to correlate well with blood concentrations¹³⁴. In addition, urine does not typically undergo proteolytic degradation, as with other blood-derived fluids, greatly extending protein lifetime and stability¹³⁵. However, biomolecules tend to exist in urine at much lower concentrations than in blood, which can complicate detection^134,135. Furthermore, the long filtration process of urine production reflects analyte concentrations over long time frames, which makes analysis of transient conditions difficult¹³⁶. The use of urine in biomolecular sensors is rare, but it still may be advantageous over other fluids in diagnosing reproductive cancers¹³⁵, sexually transmitted diseases¹³⁷ and other urogenital conditions. Urine has also been explored as a potential fluid for wearable sensor analysis (for example, in diapers)¹³⁸.

Blood

Blood is the most information-rich biological fluid in the body owing to its ubiquitous involvement in homeostasis and transport. Because of the diverse biomolecular composition of blood, blood analysis has long served as the gold standard for physiological diagnosis. Many other body fluids, including interstitial fluid (ISF), saliva, tears and urine are derived from blood, making it an excellent reference for alternative fluid comparison. Blood is being explored as a potential fluid for in vivo body-based sensors¹³⁹; however, its sampling tends to be invasive and risks systemic infections. In addition, blood contains high concentrations of cells and proteins, which can cause biofouling and decrease the stability and reliability of sensors over time. Although blood still serves as an excellent fluid for laboratory-based analysis and sensor comparison, blood derivatives are favoured in the development of body-based sensors.

Saliva

Saliva can be easily collected or stimulated¹⁴⁰, and has a diverse molecular composition. Although saliva is 99% water, it also contains an abundance of small molecules, proteins, DNA, and other molecular signatures that can be used to monitor physiology and diagnose disease¹⁴¹. Saliva is derived from blood plasma; however, its biochemical composition has little correlation with that of whole blood¹⁴². Therefore, the use of salivary markers to monitor physiology requires independent validation and testing. Saliva–blood glucose comparisons show decent similarity, with lag times of approximately 15 minutes¹⁴³. Body-based sensing wearables for the analysis of saliva include mouthguards and pacifiers that can continuously monitor small molecules^144,145. Unlike physiological markers, exogenous analytes, such as those from bacteria or viruses, are typically used in presence-based detection, which makes saliva an ideal testing fluid for infectious diseases^141,146.

Sweat

Sweat can be non-invasively collected for physiological monitoring¹⁴⁷. Small-molecule concentrations in sweat have demonstrated good correlation with blood, with a reported lag time of 10 minutes for glucose¹⁴⁸. However, although wearable sweat sensors have been developed for ions and other small molecules^20,55,149, sweat-based detection of proteins and other large molecules remains a challenge¹⁵⁰. Protein concentrations in sweat correlate with blood concentrations in some instances¹⁵¹, but have remained difficult to reliably detect owing to their trace concentrations, often unexplored physiological correlation, and a lack of biomarker-focused sweat proteomic analyses^147,152. Despite these hurdles, protein sensing in sweat has had some success (for example, in the detection of cytokines^153,154) and has the potential to advance considerably as the physiological distribution of proteins in sweat becomes clearer¹⁵⁰.

Sweat collection and sampling is straightforward as its secretion can be stimulated through heat, stress, chemicals or iontophoresis in addition to passive release^147,155. However, the partitioning of analytes into sweat varies with the different stimulation approaches¹⁵⁵. Furthermore, sweat composition is largely dependent on sweat rate, which influences the degree of analyte dilution¹⁵⁵. Ionic strength differences among sweat collection conditions alter the electric double layer of electronic surfaces, which complicates detection schemes that rely on stable Debye parameters^51,52. Sweat-based wearables can be incorporated into everyday life in the form of watches, tattoos or any other product in contact with skin¹⁵⁶.

Tears

Tears have gained attention as a non-invasive fluid for biomolecular analysis owing to their external secretion and diverse biochemical composition, including metabolites, small molecules and proteins¹⁵⁷. Although tear composition can differ substantially from that of blood, many tear-based analytes correlate closely with their corresponding blood concentrations¹⁵⁸. Tear analyte concentrations lag behind those of blood, with a recorded lag time of approximately 13 minutes for glucose¹⁵⁹. Advances in flexible electronics have allowed the development of fully integrated contact lenses that can sample tears without user intervention¹⁵⁸ for continuous monitoring of tear glucose^160,161. However, tear-based sensors face several challenges, including small sample volumes, fast evaporation rates and variations in tear secretion rates and composition depending on their source of stimulation^162–164.

Interstitial fluid

ISF is a promising fluid for biomolecular analysis, owing to its compositional similarity to blood and potential for non-invasive collection¹⁶⁵. Analyte partitioning between blood and ISF occurs mainly through continuous capillaries owing to high capillary densities, low flow rates and the ability to exchange even very large proteins (up to 1 MDa). Therefore, many analytes pass easily between these two fluids and have near-equal concentrations in both¹⁵⁵. However, larger analytes (for example, proteins >10 kDa) typically exist at lower concentrations in ISF owing to their reliance on more complex transport pathways, with their ISF concentrations varying inversely with the logarithm of their molecular weight¹⁶⁶. Analyte changes in blood are also detected quickly in ISF, with the lag time for glucose being approximately 5–6 minutes behind that of blood¹⁶⁷. Although ISF-based continuous glucose monitors have been commercialized (for example, Dexcom’s G6 and Abbott’s FreeStyle Libre continuous glucose monitoring system¹⁶⁸), there remains a demand for robust and simple ISF collection approaches with high extraction efficiency and resistance to potential contamination¹⁵⁵. Microneedle patches, containing arrays of micrometre-sized needles, can be used to sample large volumes of ISF non-invasively^169,170. Although ISF-based glucose sensing has been extensively optimized, fundamental research into ISF analyte partitioning, physiological correlation and lag times will be needed to allow the detection of other analytes¹⁷¹.

Breath

Breath contains volatile organic compounds, proteins, fatty acids and germ particles that can provide valuable information on physiology and disease¹⁷². Although the diversity and quantity of biologically relevant molecules in breath is lower than in other biological fluids, biomolecular breath sensors can be applied to detect small molecules, proteins and viruses^172–174. In addition, synthetic biomarkers (for example, protease-responsive nanoparticles) may enable breath-based detection of various physiological conditions (for example, alpha-1 antitrypsin deficiency)²⁴. Breath analysis can also be implemented in wearable sensors (such as masks) that can directly sample analytes from exhaled air¹³².

Digestive fluids

Digestive fluids may be analysed by consumable electronics (for example, diagnostic pills). The molecular biomarkers within digestive fluids are still being explored, but contain an abundance of biochemical information relating to health (for example, gut microbiota)¹⁷⁵ and disease (for example, digestive system cancers)¹⁷⁶. Unlike other bodily fluids, digestive fluids are characterized by high acidity and abundant enzymes, requiring highly resilient sensors¹⁷⁷. Optical and electrochemical sensors can continuously monitor analytes within these harsh environments (for example, through amperometric detection of glucose in gastric and intestinal fluids¹⁷⁸) and demonstrate success in animal models (for example, detecting gastrointestinal bleeding in swine using a wireless optical readout capsule specific for haem)¹⁷⁹. Such consumable biomolecular sensors may improve access to and analysis of the gastrointestinal tract¹⁸⁰.

Outlook

Biomolecular sensing has drawn substantial attention during the ongoing SARS-CoV-2 pandemic, with the rapid development and implementation of viral antigen tests demonstrating the power of such sensors to provide easy access to health information. Whereas glucose monitoring has traditionally dominated the biomolecular sensing landscape, body-based bioelectronic devices have sparked immense interest in the development of continuous sensors for alternative analytes that can operate in many body fluids¹⁸⁰.

The development of body-based biomolecular sensors requires flexible and biocompatible electronic materials that can seamlessly interface with soft biological tissues and that can be manufactured using inexpensive, facile and easily scalable methods^20,181. Materials such as conductive hydrogels and laser-engraved graphene can serve as sensing platforms^20,182. Additionally, plastics and organic materials can serve as substrates and semiconductors benefiting from cost-efficiency, flexibility and potential biodegradability¹⁸³. Metals that are fluid at room temperature (for example, gallium) also hold great promise for soft electronics development¹⁸⁴. Application-dependent material considerations are also essential in body-based sensor development; for example, wearable sensors that can be integrated into clothing as smart textiles are non-intrusive and allow dispersed units to communicate easily^185,186. Moreover, implantable sensors made with biofilm-resistant materials are resilient to internal physiological conditions¹⁸⁷, and consumable sensors made with edible, biosafe materials are safe for user ingestion¹⁸⁸. In addition, materials that can harvest biochemical or biomechanical energy (for example, biofuel cells¹⁸⁹, triboelectric generators¹⁹⁰ and piezoelectric generators¹⁹¹), store energy (for example, supercapacitors¹⁹²), and enable multi-sensor communication (for example, surface-plasmon-like metamaterials¹⁹³) will likely prove vital in the evolution of body-based platforms.

However, the clinical translation of biomolecular sensors will require proof of safety. Sensors must be sanitized prior to implementation¹⁹⁴, have low component toxicity¹⁹⁵ and minimal immunogenicity¹⁹⁶. Furthermore, sensors must produce minimal irritation and stimuli (for example, loud sounds and bright lights) and they should be comfortable to wear¹⁹⁷. Moreover, devices must be resistant to cyberattacks or other intrusive events¹⁹⁸ and ensure user data protection¹⁹⁹.

Body-based sensing systems will also advance sensing applications, such as in personalized healthcare to provide tailored diagnoses, interventions and management plans through access to real-time, patient-specific biomolecular data. Using this technology, it may be possible to identify effective drugs for different illnesses²⁰⁰, monitor and optimize drug dosages²⁰¹, and detect early signs of disease. In addition, body-based sensors can provide preventative information, through metabolic and nutritional profiles, for example, to improve patient health and avoid disease²⁰². Body-based systems also show promise in the development of advanced closed-loop systems, such as an artificial pancreas device capable of monitoring and delivering insulin, for the treatment of diabetes²⁰³. In addition to diabetes, these closed-loop systems may allow the treatment of various health conditions related to biomolecular deficiencies (for example, neural chemical imbalances and iron-deficiency anaemia).

The next generation of biomolecular sensors aims to advance biomolecular analysis by using advanced body-based systems to detect diverse analytes in complex biological environments. However, there are outstanding challenges regarding adequate signal amplification (for example, the need for enhanced sensitivity and flexible LoDs), practical continuous measurements (for example, the need for regenerable sensing approaches), biological fluid composition (for example, the need for strategies to overcome interferences in complex media), and device integration (for example, the need for reliable and practical sensors) that must be addressed prior to widespread adoption.

Citation diversity statement

We acknowledge that papers authored by scholars from minoritized groups are systematically under-cited. Here, we have made every attempt to reference relevant papers in a manner that is equitable in terms of racial, ethnic, gender and geographical representation.

Author contributions

All authors contributed to the writing of the manuscript. C.D.F. and S.O.K. edited the manuscript.

Peer review

Peer review information

Nature Reviews Bioengineering thanks Chunhai Fan and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Competing interests

S.O.K. and H.Y. are cofounders and equity holders in Arma Biosciences, which is commercializing new sensing technologies.